# Clinical effectiveness and side effects of different treatment methods for lung cancer

| Submission date           | <b>Recruitment status</b><br>No longer recruiting | Prospectively registered    |  |  |
|---------------------------|---|-----------------------------|--|--|
| 11/10/2022                |   | [] Protocol                 |  |  |
| Registration date         | Overall study status                              | Statistical analysis plan   |  |  |
| 22/10/2022                | Completed   | [X] Results                 |  |  |
| Last Edited<br>20/04/2023 | <b>Condition category</b><br>Cancer               | Individual participant data |  |  |

## Plain English summary of protocol

Background and study aims

The aim of this study is to assess the clinical effectiveness and side effects of different treatments for lung adenocarcinoma (the most common type of lung cancer).

Who can participate? Late-stage lung adenocarcinoma patients admitted to the oncology department

#### What does the study involve?

Patients are separated into four different groups according to their gene mutation status. The four groups are treated with targeted drugs or targeted drugs combined with chemotherapy. The difference in recent treatment effects and the occurrence of adverse reactions in the seven groups are compared. Every chemotherapy cycle lasts 3 weeks. Four to six cycles are given depending on the patient's recovery and tolerance. Patients stopped taking the medication when they could not tolerate the side effects or the disease progressed.

What are the possible benefits and risks of participating? The patients are treated professionally for their disease. There are no risks of participating.

Where is the study run from? Fujian Provincial Hospital (China)

When is the study starting and how long is it expected to run for? January 2017 to October 2020

Who is funding the study? Tianqing Medical Science Development Fundl (China)

Who is the main contact? Ting Li, fjslzjp@163.com

# **Contact information**

## Type(s)

Public

**Contact name** Dr Ting Li

### **Contact details**

Department of Oncology Shengli Clinical Medical College of Fujian Medical University Fujian Provincial Hospital Fuzhou China 350001 +86 (0)15711393692 fjslzjp@sina.com

# Additional identifiers

**EudraCT/CTIS number** Nil known

#### **IRAS number**

**ClinicalTrials.gov number** Nil known

**Secondary identifying numbers** Nil known

# Study information

#### Scientific Title

Observation on the clinical efficacy and side effects of EGFR-TKI ± chemotherapy in the treatment of EGFR mutation-positive advanced lung adenocarcinoma

#### **Study objectives**

To assess the clinical efficacy and side effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with or without chemotherapy in the treatment of EGFR mutation-positive advanced lung adenocarcinoma.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Approved 26/11/2021, Fujian Provincial Hospital Ethics Committee (Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, No.134 East Street, Fuzhou, Fujian 350001, China; +86 (0)591 87557768; fjslec@163.com), ref: NUMBER/ID:K2021-11-010

#### Study design

Single-center observational cohort study

## Primary study design

Observational

**Secondary study design** Cohort study

**Study setting(s)** Hospital

**Study type(s)** Treatment

#### Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

#### Health condition(s) or problem(s) studied

EGFR mutation-positive advanced lung adenocarcinoma

#### Interventions

103 EGFR mutation-positive stage IIIB or IV lung adenocarcinoma patients were enrolled in the department of oncology of Fujian Provincial Hospital from January 2017 to October 2020. According to gene mutation status, 103 EGFR-sensitive mutation patients were separated into four different groups: 19del alone, 19del combined with TP53 or other co-mutations, L858R alone, and L858R mutation combined with TP53 or other co-mutations. The four groups were respectively treated with targeted drugs or targeted drugs combined with chemotherapy. In the 19del alone group only targeted drugs were used and no chemotherapy was applied. The difference in recent treatment effects and the occurrence of adverse reactions in the seven groups were compared. Chemotherapy regimen: pemetrexed disodium 500 mg/ m2D1 cisplatin 25 mg/ m2D1-3 or carboplatin AUC5 were given intravenously. Every chemotherapy cycle lasted 3 weeks. Four to six cycles were given depending on the patient's recovery and tolerance. Targeted drug therapy: oral gefitinib tablets (Iressa, national drug approval J20180014, AstraZeneca Pharmaceutical Co., Ltd) 250 mg/day, once a day, patients took it orally until the end of follow-up. Patients stopped taking the medication when they could not tolerate the side effects or the disease progressed.

#### Intervention Type

Drug

**Phase** Not Applicable

#### Drug/device/biological/vaccine name(s)

Pemetrexed disodium, cisplatin, carboplatin, gefitinib

#### Primary outcome measure

1. Long-term efficacy: tumor progression-free survival (PFS) and survival calculated from enrollment to 1-year and 3-year follow-up

2. Adverse effects: the occurrence and severity of adverse events, including acute central nervous system adverse reactions, acute radiation pneumonia, vomiting, nausea, rash, diarrhea,

liver function damage, and bone marrow suppression, using the commonly used term evaluation criterion (CTCAE4.0) of the National Cancer Center of Adverse Events and the tumor radiotherapy group (RTOG) classification standard. Calculated at 1-year and 3-year follow-up

#### Secondary outcome measures

1. Size and metastasis of the target tumor determined using head MRI, chest and abdomen CT (including adrenal gland), bone X-ray or MRI, or whole body PET-CT and other examinations before treatment and 12 weeks after treatment

2. Short-term efficacy: According to the WHO criteria for evaluation of solid tumor efficacy (RECIST1.1), patients were separated into progressive response (PD), stable response (SD), partial response (PR) and complete response (CR) groups. CR: indicated that all lymph nodes had shrunk to less than 10 mm and all visible lesions were cleared and maintained for at least a month; PR: the sum of the maximum diameters of all target tumors was reduced by more than 30% from baseline and remained stable for at least a month; PD: signifies that there is more than 20% growth in the sum of all target tumor maximum diameters from the minimum, and there are at least 5 mm increases in the absolute value of the maximum diameters, or that one or more new lesions emerge; SD stands for the status between PR and PD. ORR= (CR+PR)/total number of cases ×100%.

#### Overall study start date

01/01/2017

## **Completion date**

01/10/2020

# Eligibility

#### Key inclusion criteria

- 1. Initial treatment of lung adenocarcinoma confirmed by pathology or cytology
- 2. Classic mutation of EGFR gene
- 3. Minimum life expectancy 3 months

4. Patients with clinical stage III ~ IV were considered as advanced lung cancer after comprehensive evaluation of imaging, medical history and examination at the same time, and were excluded from other malignant tumors

#### Participant type(s)

Patient

## Age group

Mixed

**Sex** Both

**Target number of participants** 80

**Total final enrolment** 103 **Key exclusion criteria** Does not meet the inclusion criteria

Date of first enrolment 01/01/2017

Date of final enrolment 01/09/2020

## Locations

**Countries of recruitment** China

**Study participating centre Fujian Provincial Hospital** No.134 East Street Fuzhou China 350001

# Sponsor information

**Organisation** Fujian Provincial Hospital

## Sponsor details

No.134 East Street Fuzhou China 350001 +86 (0)591 87557768 unionqyye@163.com

**Sponsor type** Hospital/treatment centre

Website http://www.fjsl.com.cn/

ROR https://ror.org/045wzwx52

# Funder(s)

**Funder type** Research organisation

#### Funder Name

Tianqing Medical Science Development Fund

# **Results and Publications**

#### Publication and dissemination plan

Planned publication in a peer-reviewed journal.

#### Intention to publish date

30/11/2022

#### Individual participant data (IPD) sharing plan

Raw data can be obtained by contacting Ting Li (fjslzjp@163.com). The type of data: Patients' information in Excel format. Duration: Forever available. The data will be shared with researchers who also study lung cancer, for dataset analysis, using statistical methods. Consent from participants was obtained. Data were anonymized.

#### IPD sharing plan summary

Available on request

#### Study outputs

| Output type     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|-----------------|---------|--------------|------------|----------------|-----------------|
| Results article |         | 12/12/2022   | 20/04/2023 | Yes            | No              |